In-vivo quantitative imaging of catecholaminergic nerve terminals in brain and peripheral organs using positron emission tomography (PET)

  • I. J. Kopin
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)


Positron emission tomogaphy (PET), has made possible quantitative imaging of the origins of positron-emitting isotopes, such as 11C and 18F, in intact animals and in humans. Lack of absolute specificity of enzymes, storage mechanisms and transporters allows 11C-or 18F-labelled “false transmitters” to be formed, stored and released from nerve terminals. Discussed are the assumptions, limitations, and advantages of 18F-6-fluoroDOPA, 18F-6-fluorodopamine, 18F-6-fluorometaraminol, and 11C-N-methyl-metaraminol (m-hydroxyephedrine) for PET imaging of dopaminergic nerve terminals in brain or sympathetic innervation in peripheral organs.


Sympathetic Nerve Sympathetic Innervation Sympathomimetic Amine Sympathetic Nerve Terminal Sympathetic Nerve Stimulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aquilonius SM, Langstrom B, Tedroff J (1989) Brain dopaminergic mechanisms in Parkinson’s disease evaluated by positron emission tomography. Acta Neurol Scand 126:55–59.CrossRefGoogle Scholar
  2. Calne DB, Langston JW, Martin WR, Stoessl AJ, Ruth TJ, Adam MJ, Pate BD, Schulzer M (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson’s disease. Nature 317:246–8.PubMedCrossRefGoogle Scholar
  3. Carlsson A, Lindquist M (1962) In-vivo decarboxylation of a-methyl dopa and α-methyl metatyrosine. Acta Physiol Scand 54:87–94.PubMedCrossRefGoogle Scholar
  4. Chiueh CC, Zukowska-Grojec Z, Kirk KL, Kopin IJ (1983) 6-Fluorocatecholamines as false adrenergic transmitters. J Pharmacol Exp Ther 225:529–533.PubMedGoogle Scholar
  5. Chiueh CC, Firnau G, Burns RS, Nahmias C, Kopin IJ, Garnett ES (1987) Determination and visualization of damage to striatal dopaminergic terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by [18-F]-labeled 6-fluoro-L-dopa and positron emission tomography. Adv Neurol 45:167–169.PubMedGoogle Scholar
  6. Crout JR, Alpers HS, Tatum EL, Shore PA (1964) Release of metaraminol from the heart by sympathetic nerve stimulation. Science 145:828–829.PubMedCrossRefGoogle Scholar
  7. Day MD, Rand MJ (1963) A hypothesis for the mode of action of α-methyldopa in relieving hypertension. J Pharm Pharmacol 15:221–224.PubMedCrossRefGoogle Scholar
  8. Doudet DJ, Myack H, Finn RT, McLellan CA, Aigner TG, Wan RQ, Adams HR, Cohen RM (1989) 6-18F-L-dopa imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys. Exp Brain Res 78(1):69–80.PubMedCrossRefGoogle Scholar
  9. Eisenhofer G, Hovevey-Sion D, Kopin IJ, Miletich R, Kirk KL, Finn R, Goldstein DS (1989) Neuronal uptake and metabolism of 2-and 6-fluorodopamine. False transmitters for positron emission tomographic imaging of sympathetically innervated tissues. J Pharmacol Exp Ther 248:419–427.Google Scholar
  10. Firnau G, Garnett ES, Chirakal R, Sood S, Nahmias C, Schrobilgen G (1986) [18F] fluoro-L-dopa for the in vivo study of intracerebral dopamine. Int J Rad Appl Instrum [A] 37(8):669–675.CrossRefGoogle Scholar
  11. Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES (1987) Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 48(4): 1077–1082.PubMedCrossRefGoogle Scholar
  12. Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES (1988) Metabolites of 6-[18F]fluoro-L-dopa in human blood. J Nucl Med 29(3):363–369.PubMedGoogle Scholar
  13. Fischer JE, Horst WD, Kopin IJ (1965) β-Hydroxylated sympathomimetic amines as false neurotransmitters. Br J Pharmacol 24:477–484.Google Scholar
  14. Garnett ES, Firnau G, Chan PKH, Sood S, Belbeck LW (1978) [18F] Fluorodopa, an analogue of dopa, and its use in direct external measurements of storage degradation and turnover of intracerebral dopamine. Proc Natl Acad Sci USA 75:464–467.PubMedCrossRefGoogle Scholar
  15. Garnett ES, Firnau G, Nahmias C (1983) Dopamine visualized in the basal ganglia of living man. Nature 205:137–138.CrossRefGoogle Scholar
  16. Garnett ES, Firnau G, Nahmias C, Chirakal R (1983) Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res 280:169–171.PubMedCrossRefGoogle Scholar
  17. Goldstein DS, Chang PC, Eisenhofer G, Miletich R, Finn R, Bacher J, Kirk KL, Bacharach S, Kopin IJ (1990) Positron emission tomographic imaging of cardiac sympathetic innervation and function. Circulation 81:1606–1621.PubMedCrossRefGoogle Scholar
  18. Guttman M, Yong VW, Kim SU, Calne DB, Martin WR, Adam MJ, Ruth TJ (1988) Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys. Synapse 2:469–473.PubMedCrossRefGoogle Scholar
  19. Herman W, Graefe KH (1977) Relationship between the uptake of 3H-Metaraminol and the density of adrenergic innervation in isolated rat tissues. Arch Pharm 296:99–110.CrossRefGoogle Scholar
  20. Hertting G, Axelrod J (1961) Fate of tritiated norepinephrine at the sympathetic nerve ending. Nature 192:172–173.PubMedCrossRefGoogle Scholar
  21. Hertting G, Axelrod J, Kopin IJ, Whitby LC (1961) Lack of uptake of catecholamine after chronic denervation of sympathetic nerves. Nature 189:66.PubMedCrossRefGoogle Scholar
  22. Hertting G, Potter LT, Axelrod J (1962) Effect of decentralization and ganglion blocking agents on the spontaneous release of 3H-norepinephrine. J Pharmacol Exp Ther 136:289–292.PubMedGoogle Scholar
  23. Iversen LL (1965a) The uptake of catecholamines at high perfusion concentrations in the rat isolated heart: a novel catecholamine uptake process. Br J Pharmacol 25:18–33.Google Scholar
  24. Iversen LL (1965b) Inhibition of noradrenaline uptake by drugs. J Pharm Pharmacol 17:52–64.CrossRefGoogle Scholar
  25. Kopin IJ (1968) False adrenergic transmitters. Ann Rev Pharmacol 8:377–394.PubMedCrossRefGoogle Scholar
  26. opin IJ, Gordon EK, Horst WD (1965) Studies of uptake of L-norepinephrine-14C. Biochem Pharmacol 14:753–759.CrossRefGoogle Scholar
  27. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T, Marsden CD (1986a) Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49:853–860.PubMedCrossRefGoogle Scholar
  28. Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RS (1986b) Inhibition of L[18F]fluorodopa uptake into human brain amino acids demonstrated by positron emission tomography. Ann Neurol 20:258–262.PubMedCrossRefGoogle Scholar
  29. Lundborg P, Stitzel R (1967) Uptake of biogenic amines by two different mechanisms present in adrenergic granules. Br J Pharmacol 39:249–342.Google Scholar
  30. Musacchio JM, Kopin IJ, Weise VK (1965) Subcellular distribution of some sympathomimetic amines and their β-hydroxylated derivatives in the rat heart. J Pharmacol Exp Ther 148:22–28.PubMedGoogle Scholar
  31. Muscholl E, Maitre L (1963) Release by sympathetic stimulation of α-methylnoradrenaline stored in the heart after administration of α-methyldopa. Experientia 19:658–659.PubMedCrossRefGoogle Scholar
  32. Oates JA, Gillespie I, Udenfriend S, Sjoerdsma A (1960) Decarboxylase inhibition and blood pressure reduction by α-methyl-3,4-dihydroxy-D,L-phenylalanine. Science 131:1890–1891.PubMedCrossRefGoogle Scholar
  33. Rosenberg NL, Myers JA, Martin WR (1989) Cyanide-induced parkinsonism: clinical, MRI, and 6-fluorodopa PET studies. Neurology 39:142–144.PubMedGoogle Scholar
  34. Samorajski T, Marks BN, Webster EJ (1964) An autoradiographic study of the uptake and storage of norepinephrine-3H in tissues of mice treated with reserpine and cocaine. J Pharmacol Exp Ther 143:82–89.PubMedGoogle Scholar
  35. Schwaiger M, Hutchins GD, Rosenspire K, Haka MS, Weiland DM (1990) Quantitative evaluation of the sympathetic nervous system in patients with cardiomyopathy. J Nucl Med 31:792.Google Scholar
  36. Sourkes TL (1954) Inhibition of dihydroxyphenylalanine decarboxylase by derivatives of phenylalanine. Arch Biochem Biophys 51:444–456.PubMedCrossRefGoogle Scholar
  37. Wieland DM, Rosenspire KC, Hutchins GD, Vandort M, Rothley JM, Mislankar SG, Lee HT, Massin CC, Gildersleeve DL, Sherman PS, Schwaiger M (1990) Neuronal mapping of the heart with 6-[18F]fluorometaraminol. J Med Chem 33:956–964.PubMedCrossRefGoogle Scholar
  38. Wolters EC, Huang CC, Clark C, Peppard RF, Okada J, Chu NS, Adam MJ, Ruth TJ, Li D, Calne DB (1989) Positron emission tomography in manganese intoxication. Ann Neurol 26(5):647–651.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • I. J. Kopin
    • 1
  1. 1.NINDS, National Institute of HealthBethesdaUSA

Personalised recommendations